Goldman Sachs
BCAB icon

Goldman Sachs’s BioAtla BCAB Stock Holding History

Goldman Sachs’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-607
Closed -$17.9K – 6056
2024
Q4 		$17.9K Buy
+607
New +$50.9K ﹤0.01% 5907
2024
Q3 		– Sell
-7,178
Closed -$492K – 5815
2024
Q2 		$492K Buy
7,178
+6,234
+660% +$742K ﹤0.01% 4841
2024
Q1 		$162K Buy
944
+169
+22% +$21K ﹤0.01% 5164
2023
Q4 		$95.3K Sell
775
-208
-21% -$18K ﹤0.01% 5300
2023
Q3 		$83.5K Sell
983
-661
-40% -$84.2K ﹤0.01% 5213
2023
Q2 		$247K Buy
1,644
+509
+45% +$87.5K ﹤0.01% 5107
2023
Q1 		$152K Sell
1,135
-726
-39% -$131K ﹤0.01% 5379
2022
Q4 		$768K Sell
1,861
-245
-12% -$102K ﹤0.01% 4594
2022
Q3 		$811K Buy
2,106
+559
+36% +$183K ﹤0.01% 4658
2022
Q2 		$220K Sell
1,547
-2,161
-58% -$344K ﹤0.01% 5598
2022
Q1 		$927K Buy
3,708
+2,644
+248% +$1.11M ﹤0.01% 4881
2021
Q4 		$1.04M Buy
1,064
+130
+14% +$166K ﹤0.01% 4802
2021
Q3 		$1.38M Buy
934
+705
+308% +$1.37M ﹤0.01% 4503
2021
Q2 		$485K Sell
229
-168
-42% -$380K ﹤0.01% 5246
2021
Q1 		$1.01M Sell
397
-1,703
-81% -$4.37M ﹤0.01% 4601
2020
Q4 		$3.57M Buy
+2,100
New +$3.51M ﹤0.01% 3273

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Goldman Sachs's BCAB Position: Q1 2025 in Review

Goldman Sachs sold out of BioAtla (BCAB) in Q1 2025, closing a stake of 607 shares — an estimated $17.9K sold.

Goldman Sachs first reported a position in BCAB in Q4 2020 and held it in 16 quarters. The position peaked at $3.57M in Q4 2020. 41 funds tracked by Wall St. Rank hold BCAB as of Q1 2025.

  • Goldman Sachs reported no remaining BioAtla position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 607 BioAtla shares in Q1 2025, an estimated $17.9K.
  • Goldman Sachs first reported a position in BioAtla in Q4 2020 and held it in 16 quarters.
  • Goldman Sachs's BioAtla position peaked at $3.57M in Q4 2020.
  • 41 funds tracked by Wall St. Rank held BioAtla as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.